Scholar Rock Phase 2 EMBRAZE trial shows 54.9% lean mass preservation with apitegromab plus tirzepatide (p=0.001)

Scholar Rock Holding Corp

Primary endpoint met: apitegromab + tirzepatide preserved 54.9% of lean mass (p=0.001) vs tirzepatide alone over 24 weeks.
Patients on combination lost 18.8 lbs fat mass vs 17.7 lbs for tirzepatide alone; total weight loss 12.3% vs 13.4%.
Quality of weight loss improved: 85% fat / 15% lean mass loss with combination vs 70% fat / 30% lean with tirzepatide alone.
Apitegromab well tolerated; no SAEs or discontinuations related to apitegromab, consistent with prior studies.
Company plans to file IND for next-gen SRK-439 in H2 2025; conference call today at 8 AM EDT.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.